Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
MannKind Corporation is a biotechnology business based in the US. MannKind Corporation shares (MNKD) are listed on the NASDAQ and all prices are listed in US Dollars. MannKind Corporation employs 240 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $3.93 |
|---|---|
| 52-week range | $3.12 - $6.25 |
| 50-day moving average | $4.43 |
| 200-day moving average | $4.47 |
| Wall St. target price | $6.25 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.32 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.93 from 2022-01-20
| 1 week (2022-01-14) | 0.26% |
|---|---|
| 1 month (2021-12-22) | -10.88% |
| 3 months (2021-10-22) | -15.30% |
| 6 months (2021-07-22) | -12.28% |
| 1 year (2021-01-22) | 11.02% |
|---|---|
| 2 years (2020-01-22) | 132.54% |
| 3 years (2019-01-22) | 180.71% |
| 5 years (2017-01-20) | 515.89% |
| Revenue TTM | $81.4 million |
|---|---|
| Gross profit TTM | $40.5 million |
| Return on assets TTM | -12.77% |
| Return on equity TTM | 0% |
| Profit margin | -97.43% |
| Book value | $-1.04 |
| Market capitalisation | $984.9 million |
TTM: trailing 12 months
We're not expecting MannKind Corporation to pay a dividend over the next 12 months.
MannKind Corporation's shares were split on a 1:5 basis on 2 March 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MannKind Corporation shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for MannKind Corporation shares which in turn could have impacted MannKind Corporation's share price.
Over the last 12 months, MannKind Corporation's shares have ranged in value from as little as $3.12 up to $6.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MannKind Corporation's is 1.7547. This would suggest that MannKind Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-ß inhibitor for the treatment of pulmonary fibrosis. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. .
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.